%PDF-1.4
%
39 0 obj
<>
endobj
36 0 obj
<>
endobj
115 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-07-29T18:27:07Z
2024-03-28T07:58:41-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T07:58:41-07:00
application/pdf
Heather
2002-1098.sept
uuid:4088c3aa-1dd2-11b2-0a00-f709275dc400
uuid:4088c3ad-1dd2-11b2-0a00-810000000000
endstream
endobj
25 0 obj
<>
endobj
26 0 obj
<>
endobj
40 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 13 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 15 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 17 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 19 0 R/Type/Page>>
endobj
131 0 obj
[136 0 R]
endobj
132 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(of antibodies to lipid antigens. J Immunol Methods 1980;38:85-93.)Tj
-2.175 -1.25 Td
[(17.)-875 (Harris EN, Gharavi )55 (AE, Boey ML, et al. )55 (Anticardiolipin antibodies:)]TJ
2.175 -1.25 Td
(detection by radioimmunoassay and association with thrombosis in)Tj
0 -1.25 TD
[(systemic lupus erythematosus. Lancet 1983;2:121)37 (1-4.)]TJ
-2.175 -1.25 Td
[(18.)-875 (Loizou S, McCrea JD, Rudge )55 (A, Reynolds )55 (A, Boyle CC, Harris)]TJ
2.175 -1.25 Td
(EN. Measurement of anticardiolipin antibodies by an enzyme-)Tj
T*
(linked immunosorbent assay \(ELISA\): standardization and)Tj
T*
(quantitation of results. Clin Exp Immunol 1985;62:738-45.)Tj
-2.175 -1.25 Td
[(19.)-875 (Hughes GR)80 (V)129 (. )18 (The anticardiolipin syndrome. Clin Exp Rheumatol)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1985;3:285-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875 (Delez\216 M, Oria CV)129 (, )55 (Alarc\227n-Segovia D. Occurrence of both)]TJ
2.175 -1.25 Td
(hemolytic anemia and thrombocytopenic purpura \(Evans\325)Tj
T*
(syndrome\) in systemic lupus erythematosus. Relationship to)Tj
T*
[(antiphospholipid antibodies. J Rheumatol 1988;15:61)37 (1-5.)]TJ
-2.175 -1.25 Td
[(21.)-875 (Alarc\227n-Segovia D, Delez\216 M, Oria CV)129 (, et al. )55 (Antiphospholipid)]TJ
2.175 -1.25 Td
(antibodies and the antiphospholipid syndrome in systemic lupus)Tj
T*
[(erythematosus. )55 (A)-220 (prospective analysis of 500 consecutive patients.)]TJ
T*
(Medicine \(Baltimore\) 1989;68:353-65.)Tj
-2.175 -1.25 Td
[(22.)-875 (Alarc\227n-Segovia D, P\216rez-V\207zquez ME, )18 (V)60 (illa )55 (AR, Drenkard C,)]TJ
2.175 -1.25 Td
(Cabiedes J. Preliminary classification criteria for the)Tj
T*
(antiphospholipid syndrome within systemic lupus erythematosus.)Tj
T*
[(Semin )55 (Arthritis Rheum 1992;21:275-85.)]TJ
-2.175 -1.25 Td
[(23.)-875 (W)40 (ilson )18 (W)111 (A, Gharavi )55 (AE, Koike )18 (T)74 (, et al. International consensus)]TJ
2.175 -1.25 Td
(statement on preliminary classification criteria for definite)Tj
T*
(antiphospholipid syndrome: Report of an international workshop.)Tj
T*
[(Arthritis Rheum 1999;42:1309-1)37 (1.)]TJ
-2.175 -1.25 Td
[(24.)-875 (Alarc\227n-Segovia D, S\207nchez-Guerrero J. Primary antiphospholipid)]TJ
2.175 -1.25 Td
(syndrome. J Rheumatol 1989;16:482-8.)Tj
-2.175 -1.25 Td
[(25.)-875 (Asherson RA. )55 (A)-220 (\322primary\323 antiphospholipid syndrome? )]TJ
2.175 -1.25 Td
(J Rheumatol 1988;15:1742-6.)Tj
0 Tc -2.175 -1.25 Td
[(26.)-875 (Mackworth-Y)100 (oung CG, Loizou S, David J, )18 (W)80 (alport MJ. Primary)]TJ
-0.00011 Tc 2.175 -1.25 Td
(antiphospholipid syndrome: features of patients with raised)Tj
T*
[(anticardiolipin antibodies and no other disorder)55 (. )55 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(1989;48:362-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875 (Asherson RA, Khamashta MA, Ordi-Ros J, et al. )18 (The \322primary\323)]TJ
2.175 -1.25 Td
(antiphospholipid syndrome: major clinical and serological features.)Tj
T*
(Medicine \(Baltimore\) 1989;68:366-74.)Tj
-2.175 -1.25 Td
[(28.)-875 (Galli M, Comfurius P)111 (, Maassen C, et al. )55 (Anticardiolipin antibodies)]TJ
2.175 -1.25 Td
[(\(ACA\) directed not to cardiolipin but to a plasma protein cofactor)55 (.)]TJ
T*
(Lancet 1990;335:1544-7.)Tj
-2.175 -1.25 Td
[(29.)-875 (McNeil HD, Simpson RJ, Chesterman CN, Krilis SA.)]TJ
2.175 -1.25 Td
(Antiphospholipid antibodies are directed against a complex antigen)Tj
T*
(that includes a lipid-binding inhibitor of coagulation: beta-2- )Tj
T*
[(glycoprotein I \(apolipoprotein H\). Proc Natl )55 (Acad Sci USA)]TJ
0 Tc 0 Tw T*
(1990;87:4120-4.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(30.)-875 (Matsuura E, Igarashi )37 (Y)129 (, Fujimoto M, Ichikawa K, Koike )18 (T)74 (.)]TJ
2.175 -1.25 Td
[(Anticardiolipin cofactor\(s\) and dif)18 (ferential diagnosis of)]TJ
T*
(autoimmune disease. Lancet 1990;336:177-8.)Tj
-2.175 -1.25 Td
[(31.)-875 (Shoenfeld )37 (Y)129 (, Meroni PL. )18 (The beta-2-glycoprotein I and)]TJ
2.175 -1.25 Td
(antiphospholipid antibodies. Clin Exp Rheumatol 1992;10:205-9.)Tj
-2.175 -1.25 Td
[(32.)-875 (V)60 (iard JP)111 (, )55 (Amoura Z, Bach JF)80 (. )55 (Association of anti-beta2-)]TJ
2.175 -1.25 Td
(glycoprotein I antibodies with lupus-type circulating anticoagulant)Tj
T*
[(and thrombosis in systemic lupus erythematosus. )55 (Am J Med)]TJ
0 Tc 0 Tw T*
(1992;93:181-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(33.)-875 (G\227mez-Pacheco L, )18 (V)60 (illa )55 (AR, Drenkard C, Cabiedes J, Cabral )55 (AR,)]TJ
2.175 -1.25 Td
(Alarc\227n-Segovia D. Serum anti-beta 2-glycoprotein-I and)Tj
T*
(anticardiolipin antibodies during thrombosis in systemic lupus)Tj
T*
[(erythematosus patients. )55 (Am J Med 1999;106:417-23.)]TJ
-2.175 -1.25 Td
[(34.)-875 (Matsuura E, Igarashi )37 (Y)129 (, )37 (Y)100 (asuda )18 (T)74 (, )18 (T)35 (riplett DA, Koike )18 (T)74 (.)]TJ
2.175 -1.25 Td
(Anticardiolipin antibodies recognize beta 2-glycoprotein I structure)Tj
T*
(altered by interacting with an oxygen modified solid phase surface.)Tj
0 Tc T*
(J Exp Med 1994;179:457-62.)Tj
-0.00011 Tc 30.825 76.25 Td
[(35.)-875 (Roubey RAS, Eisenber)18 (g R, Harper MF)80 (, )18 (W)40 (infield JB.)]TJ
2.175 -1.25 Td
(\322Anticardiolipin\323 autoantibodies recognize beta 2-glycoprotein I i\
n)Tj
T*
[(the absence of phospholipid. Importance of )55 (Ag density and bivalent)]TJ
0 Tc T*
(binding. J Immunol 1995;154:954-60.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(36.)-875 (Cabiedes J, Cabral )55 (AR, )55 (Alarc\227n-Segovia D. Clinical manifestations)]TJ
2.175 -1.25 Td
(of the antiphospholipid syndrome in systemic lupus erythematosus)Tj
T*
(patients associate more strongly with anti-beta 2-glycoprotein-I)Tj
T*
(than with antiphospholipid antibodies. J Rheumatol 1995;)Tj
0 Tc 0 Tw T*
(22:1899-906.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(37.)-875 (Alarcon-Segovia D, Cabral )55 (AR. )55 (Antiphospholipid/cofactor)]TJ
2.175 -1.25 Td
(syndromes. J Rheumatol 1996;23:1319-22.)Tj
-2.175 -1.25 Td
[(38.)-875 (Alarcon-Segovia D. Pathogenetic potential of antiphospholipid)]TJ
2.175 -1.25 Td
(antibodies. J Rheumatol 1988;15:890-3.)Tj
-2.175 -1.25 Td
[(39.)-875 (Ruiz-Ar)18 (guelles GJ, Ru\222z-Ar)18 (g\237elles )55 (A, )55 (Alarc\227n-Segovia D, et al.)]TJ
2.175 -1.25 Td
(Natural anticoagulants in systemic lupus erythematosus. Deficiency)Tj
T*
(of protein S bound to C4bp with recent history of venous)Tj
T*
(thromboses, antiphospholipid antibodies, and the antiphospholipid)Tj
T*
(syndrome. J Rheumatol 1991;18:552-8.)Tj
-2.175 -1.25 Td
[(40.)-875 (V)111 (azquez-Mellado J, Llorente L, )55 (Alarc\227n-Segovia D. Exposure of)]TJ
2.175 -1.25 Td
(anionic phospholipid upon platelet activation permits binding of)Tj
T*
(beta 2-glycoprotein-I and through it that of IgG antiphospholipid)Tj
T*
(antibodies. Studies in platelets from patients with antiphospholipid)Tj
T*
[(syndrome and normal subjects. J )55 (Autoimmun 1994;7:335-48.)]TJ
-2.175 -1.25 Td
[(41.)-875 (Cabral )55 (AR, Cabiedes J, )55 (Alarc\227n-Segovia D. Hemolytic anemia)]TJ
2.175 -1.25 Td
(related to an IgM autoantibody to phosphatidylcholine that binds in)Tj
T*
(vitro to stored and to bromelain-treated human erythrocytes. )Tj
-0.0298 Tw T*
[(J Autoimmun )-55 (1990;3:773-87.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(42.)-875 (Del Papa N, Meroni PL, )18 (T)35 (incani )55 (A, et al. Relationship between)]TJ
2.175 -1.25 Td
(anti-phospholipid and anti-endothelial cell antibodies: further)Tj
T*
(characterization of the reactivity on resting and cytokine-activated)Tj
T*
(endothelial cells. Clin Exp Rheumatol 1992;10:37-42.)Tj
-2.175 -1.25 Td
[(43.)-875 (V)111 (aarala O, )55 (Alfthan G, Jauhiainen M, Leirisalo-Repo M, )55 (Aho K,)]TJ
2.175 -1.25 Td
[(Palosuo )18 (T)74 (. Crossreaction between antibodies to oxidised low-)]TJ
T*
(density lipoprotein and to cardiolipin in systemic lupus)Tj
T*
(erythematosus. Lancet 1993;341:923-5.)Tj
-2.175 -1.25 Td
[(44.)-875 (Blank M, Cohen J, )18 (T)70 (oder )18 (V)129 (, Shoenfeld )37 (Y)129 (. Induction of)]TJ
2.175 -1.25 Td
(antiphospholipid syndrome by passive transfer of anti-cardiolipin)Tj
T*
[(antibodies. Proc Nat )55 (Acad Sci USA)-220 (1991;88:3069-73.)]TJ
-2.175 -1.25 Td
[(45.)-875 (Blank M, Faden D, )18 (T)35 (incani )55 (A, et al. Immunization with)]TJ
2.175 -1.25 Td
(anticardiolipin cofactor \(beta 2 GP-I\) induces experimental)Tj
T*
[(antiphospholipid syndrome in naive mice. J )55 (Autoimmun)]TJ
0 Tc 0 Tw T*
(1994;7:441-55.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(46.)-875 (Blank M, Shoenfeld )37 (Y)129 (, Cabilly S, Heldman )37 (Y)129 (, Fridkin M,)]TJ
2.175 -1.25 Td
(Katchalski-Katzir E. Prevention of experimental antiphospholipid)Tj
T*
(syndrome and endothelial cell activation by synthetic peptides. Proc)Tj
T*
[(Nat )55 (Acad Sci USA)-220 (1999;96:5164-8.)]TJ
-2.175 -1.25 Td
[(47.)-875 (Blank M, Krause I, Fridkin M, et al. Bacterial induction of)]TJ
2.175 -1.25 Td
(autoantibodies to beta 2-glycoprotein-I accounts for the infectious)Tj
T*
(etiology of antiphospholipid syndrome. J Clin Invest 2002;)Tj
0 Tc 0 Tw T*
(109:797-804.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(48.)-875 (Y)100 (oshida K, )55 (Arai )18 (T)74 (, Kaburaki J, Ikeda )37 (Y)129 (, Kawakami )37 (Y)129 (, Kuwana M.)]TJ
2.175 -1.25 Td
[(Restricted )18 (T)92 (-cell receptor beta-chain usage by )18 (T)-257 (cells autoreactive)]TJ
T*
(to beta 2-glycoprotein I in patients with antiphospholipid syndrome.)Tj
0 Tc T*
(Blood 2002;99:2499-504.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(49.)-875 (Guerin J, Sheng )37 (Y)129 (, Reddel S, Iverson GM, Chapman MG, Krilis S.)]TJ
2.175 -1.25 Td
(Heparin inhibits the binding of beta 2-glycoprotein I to)Tj
T*
(phospholipids and promotes the plasmin-mediated inactivation of)Tj
T*
(this blood protein. J Biol Chem 2002;277:1-6.)Tj
ET
0 0 0 0 k
434 777 123 -27 re
f*
0 0 0 1 K
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:9)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(1896)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
19 0 obj
<>stream
8;Z\6$#U_;%+G5@W:(GfQm/AlmFc"i+N574K-Z(B6UbbJ'J3o:C@0
(,AqgG;E`!@o(6t/*-PTT1H8I4?e58OIuWTHc%M$*8b'%P_eOa.?LOnc7k^2=+6.s
IuL$&0=N2:Jed1'T"'f(_Wtj3UXTS4VHqb9bJcSh),<3'E(pg'o@W=p'j5P6pGi0jb0Y
BL.4%a.72+%up9aeDs)=m7m327qBPPgS#=XrH-L$piA_jfG%O<6FYV7Od8u5WKqTo
G.I-&/\DY&(fbPsp/*iSQc;G*5q;SA6&q+#6PdY>*hQbBoc,&/'[%&RhJhSQgk&;"
OsP;:O]kK`(GnAi@Gdlc[%"d9m$1Yl)Yg(fm&=##4mZEIq8K\[b@-N-6@>BnWM^tM
Aj&QG6iq"k=O&S-2Pg)cM,5(1Rq*I$mncnh%0Gb\&BA4Uj/0/tO3*XU#7Y@R,5Qq3
Fbg'%4,"q$_J19_i.^+YoO^R"ee5Gd@:s:mS.!MhC!d:=lNq5?:-A0Kh%VX=#a7e[
Vd))rIF8t_$tX4Y/ol%qGLks6*Q;ViNU*O2Z:>:I-0/*(TgZ]cJl['nR8[3+UF@eG
"tp?]SU0Xmn9V(5k>d9(e"sDGU@m9J(UOXM=/JS1X?!(We&?Ri%.B34\PS!(n)OS%
Gm#p+@jA:Of'i(_>/"9@YR/9K\-UB$S\VVS%A695NpU>"A..ihm.R2lN1jjM"+i(6
^='X5dSjLM(33Og'*GWsZ'?u'-nGm#T)U4FD2]QGSA+KH[dr\[]\iYRrV&jG9ua*.
HS:g0@[<&EH->qp!;()Xn,~>
endstream
endobj
23 0 obj
[/Indexed/DeviceRGB 255 22 0 R]
endobj
22 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
52 0 obj
<>
endobj
42 0 obj
<>
endobj
87 0 obj
<>
endobj
120 0 obj
<>
endobj
43 0 obj
<>
endobj
69 0 obj
<>stream
HlT{PSgpoׂ A]곶EEE( " I!o^BH #
Z+`}TmuZˌ=7~Ftgo7|3;|8fi8gsX"c[X{u#q*$gYBIM<.̃IgkqmVi2Q-gVDYa+u#R.b2H"cvEH㥉B(ҕa-)$]Kh
*ۣa?~lk?Ww;~TN=B*/;tэ_79 ؍蔭
X.?cPҏ3My#ILO`*+R)S_U ;$:G7S~=lY5^YM{'\pʌˍUT[|npu5mg32O$] N< vA@>
QxFՃ1pp+*OP83 U\/kK33*S+SO;a<ɀm{B21@ހB7t^]Fɣځ4 tT
d}JYU(9S_YJ41S Z"JcjOt&4ӣ0;ְ4ko
ױ6oK:ZyT4&v4/9:NOnߺR:dnf[с3}W)7av?jmeFޡ涱~By6e֏i}PA{7;o苺 lMzHZ)8zSҀC}y
KpPlw;%"m{l[CU#khr Ŵ:>u~mrKK2c
Ņ+{w˲A;OMNszi^o
eo~SqZƞAI2$5CެjWʒ%TuZ>V0~01h}㬕ZaDLU7G
:t XO4eDVhe깇+
o>GY$K
0XVJn`nZ3%2Lb /X.킚+#ib\~@#̟o)k(OiڲV~x GBgS?[sHׁΦ{BAJC\!kڿ&Q :n;"f$MɇEQL$6}TB[qQJM7dm 26+>kTbG%pW%@KgsbvQ)m%R}9+d7M%/+ok_c9d_jE;Er4YT~{dKƪZ
;
fyb`ŗfSz$f,ӓaM9NON<wZnsB6`DW4h=:b*D8dY:)~r; pdx)I(eO]FF(鹡cUM=6^iLWޫ"Mj)YQUԙG9 IG&p$qSZ.SQv:TE[@P$,d{!$a Y^B6!lDE-=).Tl]3y>f<Щ3
gs/TJ.uH)
8V6n ̣Lq$`< nsNx*dM:)?qs ."-Nm)tUEM {Xڄ
jxQp麁R0[wUGN#>%76K&l/Fw:?
(qω~)4ZYխ.U(PсtGZump^1O;oX5<NXE09QZDwԛ=k}w12[qW?RU6hTn4Vc Qyv|.1`}R7n5\I |<d]&}<50jX%ty6MH-Rf6[+סr;)[$cbh;mqm*M$[y&VNTb4VVY:.R[qa| ZUضsiȗaȼ0<_xĄ)vm~+31F;i$4d(L,OIUfY]LȾ=MU^Jsfm3bEZ_qFCo.a"1(v3m^AQl{
njRnE_;i67݉Yk
m~p]LAPVQ@B|)"ޯ*GMH*N;NoG"ل(sxb|MzR@0R(l$Б!.DcGeWVn9hB_r+܀+bkr&XMl5کugWWz23SK|#^#|IN'%8" +{/F$\Ť +axVO1wa}>v,KM'c/\RI{
'MiC};*|`cVb&v.j52^ &k`m4Ǹw d
w738h:<